Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease

被引:11
|
作者
Ishibashi, K. [2 ]
Kanemaru, K. [3 ]
Saito, Y. [4 ]
Murayama, S. [5 ]
Oda, K.
Ishiwata, K.
Mizusawa, H. [2 ]
Ishii, K. [1 ]
机构
[1] Tokyo Metropolitan Inst Gerontol, Positron Med Ctr, Itabashi Ku, Tokyo 1730022, Japan
[2] Tokyo Med & Dent Univ, Grad Sch, Dept Neurol & Neurol Sci, Tokyo, Japan
[3] Tokyo Metropolitan Geriatr Hosp, Dept Neurol, Tokyo 173, Japan
[4] Tokyo Metropolitan Geriatr Hosp, Dept Pathol, Tokyo 173, Japan
[5] Tokyo Metropolitan Inst Gerontol, Dept Neuropathol, Tokyo 1730022, Japan
来源
ACTA NEUROLOGICA SCANDINAVICA | 2010年 / 122卷 / 01期
基金
日本学术振兴会;
关键词
cerebrospinal fluid; dopamine transporter; homovanillic acid; Parkinson's disease; positron emission tomography; 11C-CFT; POSITRON-EMISSION-TOMOGRAPHY; HOMOVANILLIC-ACID; TRANSPORTER; PROGRESSION; DIAGNOSIS; CSF; REPRODUCIBILITY; BINDING; LIGAND;
D O I
10.1111/j.1600-0404.2009.01255.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives - To evaluate the association between cerebrospinal fluid (CSF) homovanillic acid (HVA) concentrations and nigrostriatal dopaminergic function assessed by positron emission tomography (PET) imaging with carbon-11-labeled 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)-tropane (11C-CFT), which can measure the dopamine transporter (DAT) density, in Parkinson's disease (PD). Methods - 11C-CFT PET scans and CSF examinations were performed on 21 patients with PD, and six patients with non-parkinsonian syndromes (NPS) as a control group. Results - In the PD group, CSF HVA concentrations were significantly correlated with the striatal uptake of 11C-CFT (r = 0.76, P < 0.01). However, in the NPS group, two indices were within the normal range. Conclusions - In PD, CSF HVA concentrations correlate with nigrostriatal dopaminergic function. Therefore, CSF HVA concentrations may be an additional surrogate marker for estimating the remaining nigrostriatal dopaminergic function in case that DAT imaging is unavailable.
引用
收藏
页码:46 / 51
页数:6
相关论文
共 50 条
  • [31] Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes
    Kaiserova, Michaela
    Chudackova, Monika
    Vranova, Hana Prikrylova
    Mensikova, Katerina
    Kastelikova, Anetta
    Stejskal, David
    Kanovsky, Petr
    NEURODEGENERATIVE DISEASES, 2021, 21 (1-2) : 30 - 35
  • [32] Cerebrospinal fluid carnitine levels in patients with Parkinson's disease
    JimenezJimenez, FJ
    Rubio, JC
    Molina, JA
    Martin, MA
    Campos, Y
    BenitoLeon, J
    OrtiPareja, M
    Gasalla, T
    Arenas, J
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 145 (02) : 183 - 185
  • [33] Cerebrospinal fluid nitrate levels in patients with Parkinson's disease
    Molina, JA
    JimenezJimenez, FJ
    Navarro, JA
    Vargas, C
    Gomez, P
    BenitoLeon, J
    OrtiPareja, M
    Cisneros, E
    Arenas, J
    ACTA NEUROLOGICA SCANDINAVICA, 1996, 93 (2-3): : 123 - 126
  • [34] Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
    Czech, Christian
    Berndt, Peter
    Busch, Kristina
    Schmitz, Oliver
    Wiemer, Jan
    Most, Veronique
    Hampel, Harald
    Kastler, Juergen
    Senn, Hans
    PLOS ONE, 2012, 7 (02):
  • [35] Elemental profile of cerebrospinal fluid in patients with Parkinson's disease
    Alimonti, Alessandro
    Bocca, Beatrice
    Pino, Anna
    Ruggieri, Flavia
    Forte, Giovanni
    Sancesario, Giuseppe
    JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2007, 21 (04) : 234 - 241
  • [36] Baseline Cerebrospinal Fluid α-Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline
    Emdina, Anna
    Hermann, Peter
    Varges, Daniela
    Nuhn, Sabine
    Goebel, Stefan
    Bunck, Timothy
    Maass, Fabian
    Schmitz, Matthias
    Llorens, Franc
    Kruse, Niels
    Lingor, Paul
    Mollenhauer, Brit
    Zerr, Inga
    DIAGNOSTICS, 2022, 12 (05)
  • [37] Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease
    Barschke, Peggy
    Abu-Rumeileh, Samir
    Al Shweiki, M. H. D. Rami
    Barba, Lorenzo
    Paoletti, Federico Paolini
    Oeckl, Patrick
    Steinacker, Petra
    Halbgebauer, Steffen
    Gaetani, Lorenzo
    Lewerenz, Jan
    Ludolph, Albert Christian
    Landwehrmeyer, Georg Bernhard
    Parnetti, Lucilla
    Otto, Markus
    JOURNAL OF NEUROLOGY, 2022, 269 (09) : 5136 - 5143
  • [38] Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy
    Ishigami, Noriko
    Tokuda, Takahiko
    Ikegawa, Masaya
    Komori, Mika
    Kasai, Takashi
    Kondo, Takayuki
    Matsuyama, Yumiko
    Nirasawa, Takashi
    Thiele, Herbert
    Tashiro, Kei
    Nakagawa, Masanori
    MOVEMENT DISORDERS, 2012, 27 (07) : 851 - 857
  • [39] DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
    Hong, Zhen
    Shi, Min
    Chung, Kathryn A.
    Quinn, Joseph F.
    Peskind, Elaine R.
    Galasko, Douglas
    Jankovic, Joseph
    Zabetian, Cyrus P.
    Leverenz, James B.
    Baird, Geoffrey
    Montine, Thomas J.
    Hancock, Aneeka M.
    Hwang, Hyejin
    Pan, Catherine
    Bradner, Joshua
    Kang, Un J.
    Jensen, Poul H.
    Zhang, Jing
    BRAIN, 2010, 133 : 713 - 726
  • [40] Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study
    Delgado-Alvarado, Manuel
    Dacosta-Aguayo, Rosalia
    Navalpotro-Gomez, Irene
    Gago, Belen
    Gorostidi, Ana
    Jimenez-Urbieta, Haritz
    Quiroga-Varela, Ana
    Ruiz-Martinez, Javier
    Bergareche, Alberto
    Rodriguez-Oroz, Maria C.
    MOVEMENT DISORDERS, 2018, 33 (11) : 1809 - 1814